On August 3, 2018, China State Administration of Market Regulation issued the registration information of the first complete formula for special medical purpose. Up to now, five Abbott FSMP products have been granted approval in China (in Nov., 2017, two of its partially-hydrolyzed lactoprotein infant formula were approved; in July, 2017, two formula foods for special medical purpose intended for premature or low birth weight infants were approved).